Timing of aneurysm repair after subarachnoid haemorrhage: a systematic review and meta-analysis of ultra-early and early intervention

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY
Thenul Munasinghe , Helen Huang , Thanh Phan , Leon Lai
{"title":"Timing of aneurysm repair after subarachnoid haemorrhage: a systematic review and meta-analysis of ultra-early and early intervention","authors":"Thenul Munasinghe ,&nbsp;Helen Huang ,&nbsp;Thanh Phan ,&nbsp;Leon Lai","doi":"10.1016/j.jocn.2025.111623","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The optimal timing of aneurysm repair following aneurysmal subarachnoid haemorrhage (aSAH) remains uncertain. This systematic review and <em>meta</em>-analysis evaluated whether ultra-early (≤6h), early (≤12 h), or standard (≤24 h) treatment influences rebleeding, functional outcome, or mortality.</div></div><div><h3>Methods</h3><div>A systematic search of MEDLINE, EMBASE, and Scopus identified English-language studies published between 2000 and 2024 reporting outcomes after surgical or endovascular intervention within 24 h of aSAH. Pooled odds ratios (ORs) were calculated using random-effects models. Heterogeneity was assessed using the I<sup>2</sup> statistic. Poor functional outcome was defined as modified Rankin Scale score 3–6 at 6 months.</div></div><div><h3>Results</h3><div>Twenty-one studies comprising 8,108 patients were included. Ultra-early treatment (≤6h) was associated with a reduced risk of rebleeding (OR 0.21; 95 % CI 0.06–0.77), though this was based on two studies and should be interpreted cautiously. No mortality or functional outcome data were available for this subgroup. Early treatment (≤12 h) was associated with increased rebleeding risk (OR 2.36; 95 % CI 1.44–3.89) and no significant difference in functional outcome (OR 1.01; 95 % CI 0.47–2.15). Standard treatment (≤24 h) showed a directionally favourable estimate for functional outcome (OR 0.57; 95 % CI 0.33–1.00), though statistical significance was not reached. Mortality outcomes across all timing thresholds were inconclusive, with substantial heterogeneity observed.</div></div><div><h3>Conclusion</h3><div>Ultra-early aneurysm repair may reduce rebleeding, but current evidence is limited, underpowered, and insufficient to determine effects on survival or recovery. No consistent benefit was observed with early treatment. Further prospective, time-stratified studies are needed to define the optimal intervention window following aSAH.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"141 ","pages":"Article 111623"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S096758682500596X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The optimal timing of aneurysm repair following aneurysmal subarachnoid haemorrhage (aSAH) remains uncertain. This systematic review and meta-analysis evaluated whether ultra-early (≤6h), early (≤12 h), or standard (≤24 h) treatment influences rebleeding, functional outcome, or mortality.

Methods

A systematic search of MEDLINE, EMBASE, and Scopus identified English-language studies published between 2000 and 2024 reporting outcomes after surgical or endovascular intervention within 24 h of aSAH. Pooled odds ratios (ORs) were calculated using random-effects models. Heterogeneity was assessed using the I2 statistic. Poor functional outcome was defined as modified Rankin Scale score 3–6 at 6 months.

Results

Twenty-one studies comprising 8,108 patients were included. Ultra-early treatment (≤6h) was associated with a reduced risk of rebleeding (OR 0.21; 95 % CI 0.06–0.77), though this was based on two studies and should be interpreted cautiously. No mortality or functional outcome data were available for this subgroup. Early treatment (≤12 h) was associated with increased rebleeding risk (OR 2.36; 95 % CI 1.44–3.89) and no significant difference in functional outcome (OR 1.01; 95 % CI 0.47–2.15). Standard treatment (≤24 h) showed a directionally favourable estimate for functional outcome (OR 0.57; 95 % CI 0.33–1.00), though statistical significance was not reached. Mortality outcomes across all timing thresholds were inconclusive, with substantial heterogeneity observed.

Conclusion

Ultra-early aneurysm repair may reduce rebleeding, but current evidence is limited, underpowered, and insufficient to determine effects on survival or recovery. No consistent benefit was observed with early treatment. Further prospective, time-stratified studies are needed to define the optimal intervention window following aSAH.
蛛网膜下腔出血后动脉瘤修复的时机:超早期和早期干预的系统回顾和荟萃分析
目的动脉瘤性蛛网膜下腔出血(aSAH)后最佳修复时机尚不确定。本系统综述和荟萃分析评估了超早期(≤6h)、早期(≤12h)或标准(≤24h)治疗是否会影响再出血、功能结局或死亡率。方法系统检索MEDLINE、EMBASE和Scopus,确定2000年至2024年间发表的关于aSAH术后24小时内手术或血管内介入治疗结果的英文研究。采用随机效应模型计算合并优势比(or)。采用I2统计量评估异质性。功能预后差定义为6个月时改良Rankin量表评分3-6分。结果共纳入21项研究,8108例患者。超早期治疗(≤6h)与再出血风险降低相关(OR 0.21; 95% CI 0.06-0.77),尽管这是基于两项研究,但应谨慎解释。该亚组没有死亡率或功能结局数据。早期治疗(≤12 h)与再出血风险增加相关(OR 2.36; 95% CI 1.44-3.89),功能结局无显著差异(OR 1.01; 95% CI 0.47-2.15)。标准治疗(≤24 h)对功能结局的估计方向有利(OR 0.57; 95% CI 0.33-1.00),但未达到统计学意义。所有时间阈值的死亡率结果不确定,观察到实质性的异质性。结论超早期动脉瘤修复可减少再出血,但目前的证据有限,不足,不足以确定其对生存或恢复的影响。早期治疗未观察到一致的益处。需要进一步的前瞻性、时间分层研究来确定aSAH后的最佳干预窗口。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Neuroscience
Journal of Clinical Neuroscience 医学-临床神经学
CiteScore
4.50
自引率
0.00%
发文量
402
审稿时长
40 days
期刊介绍: This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信